Clinical biology of esophageal adenocarcinoma after surgery is influenced by nuclear factor-κB expression

Julie G. Izzo, Usha Malhotra, Tsung Teh Wu, Rajalakshmi Luthra, Arlene M. Correa, Stephen G. Swisher, Wayne Hofstetter, K. S Clifford Chao, Mien Chie Hung, Jaffer A. Ajani

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: The expression of transcriptional factor nuclear factor κB (NF-κB) in untreated esophageal cancer specimens from patients who receive preoperative chemoradiation is associated with aggressive clinical biology. We hypothesized that nuclear NF-κB would define clinical biology even when surgery is used as primary therapy. Methods: Consecutive patients who did not receive any preoperative therapy were selected. Surgical cancer specimens were examined for nuclear NF-κB and correlated with overall survival (OS) and disease-free survival (DFS). Results: One hundred twenty-three patients (stage I, 9%; stage II, 24%; stage III, 53%; stage IV, 15%) with adenocarcinoma who underwent surgery as primary therapy were analyzed. Most patients were men (90%) and the median age was 63 years. For all 123 patients, the median DFS was 21 months and the median OS was 28 months. Nuclear NF-κB was associated with shortened DFS (P = 0.001) in 123 patients but also in stage II (P = 0.03) and stage III (P = 0.04). Nuclear NF-κB was associated with shortened OS (P = 0.002) in 123 patients and in stage II (P = 0.04) and showed trend in stage III (P = 0.17). Numbers are too small for stages I and IV. In multivariate models, nuclear NF-κB was an independent predictor for both DFS and OS (P = 0.005 and P = 0.01). Conclusions: Our data are the first to show that NF-κB status significantly correlates with DFS and OS for patients with esophageal adenocarcinoma undergoing surgery as primary therapy. NF-κB is an independent prognosticator of outcome, even for individual stages (e.g., stages II and III). More comprehensive molecular studies could help the design of strategies to individualize therapy of esophageal adenocarcinoma.

Original languageEnglish (US)
Pages (from-to)1200-1205
Number of pages6
JournalCancer Epidemiology Biomarkers and Prevention
Volume16
Issue number6
DOIs
StatePublished - Jun 1 2007
Externally publishedYes

Fingerprint

Adenocarcinoma
Disease-Free Survival
Survival
Therapeutics
Esophageal Neoplasms
Neoplasms

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Clinical biology of esophageal adenocarcinoma after surgery is influenced by nuclear factor-κB expression. / Izzo, Julie G.; Malhotra, Usha; Wu, Tsung Teh; Luthra, Rajalakshmi; Correa, Arlene M.; Swisher, Stephen G.; Hofstetter, Wayne; Chao, K. S Clifford; Hung, Mien Chie; Ajani, Jaffer A.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 16, No. 6, 01.06.2007, p. 1200-1205.

Research output: Contribution to journalArticle

Izzo, JG, Malhotra, U, Wu, TT, Luthra, R, Correa, AM, Swisher, SG, Hofstetter, W, Chao, KSC, Hung, MC & Ajani, JA 2007, 'Clinical biology of esophageal adenocarcinoma after surgery is influenced by nuclear factor-κB expression', Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 6, pp. 1200-1205. https://doi.org/10.1158/1055-9965.EPI-06-1083
Izzo, Julie G. ; Malhotra, Usha ; Wu, Tsung Teh ; Luthra, Rajalakshmi ; Correa, Arlene M. ; Swisher, Stephen G. ; Hofstetter, Wayne ; Chao, K. S Clifford ; Hung, Mien Chie ; Ajani, Jaffer A. / Clinical biology of esophageal adenocarcinoma after surgery is influenced by nuclear factor-κB expression. In: Cancer Epidemiology Biomarkers and Prevention. 2007 ; Vol. 16, No. 6. pp. 1200-1205.
@article{a4a2642419144919b32ac7dc67d0d4d6,
title = "Clinical biology of esophageal adenocarcinoma after surgery is influenced by nuclear factor-κB expression",
abstract = "Background: The expression of transcriptional factor nuclear factor κB (NF-κB) in untreated esophageal cancer specimens from patients who receive preoperative chemoradiation is associated with aggressive clinical biology. We hypothesized that nuclear NF-κB would define clinical biology even when surgery is used as primary therapy. Methods: Consecutive patients who did not receive any preoperative therapy were selected. Surgical cancer specimens were examined for nuclear NF-κB and correlated with overall survival (OS) and disease-free survival (DFS). Results: One hundred twenty-three patients (stage I, 9{\%}; stage II, 24{\%}; stage III, 53{\%}; stage IV, 15{\%}) with adenocarcinoma who underwent surgery as primary therapy were analyzed. Most patients were men (90{\%}) and the median age was 63 years. For all 123 patients, the median DFS was 21 months and the median OS was 28 months. Nuclear NF-κB was associated with shortened DFS (P = 0.001) in 123 patients but also in stage II (P = 0.03) and stage III (P = 0.04). Nuclear NF-κB was associated with shortened OS (P = 0.002) in 123 patients and in stage II (P = 0.04) and showed trend in stage III (P = 0.17). Numbers are too small for stages I and IV. In multivariate models, nuclear NF-κB was an independent predictor for both DFS and OS (P = 0.005 and P = 0.01). Conclusions: Our data are the first to show that NF-κB status significantly correlates with DFS and OS for patients with esophageal adenocarcinoma undergoing surgery as primary therapy. NF-κB is an independent prognosticator of outcome, even for individual stages (e.g., stages II and III). More comprehensive molecular studies could help the design of strategies to individualize therapy of esophageal adenocarcinoma.",
author = "Izzo, {Julie G.} and Usha Malhotra and Wu, {Tsung Teh} and Rajalakshmi Luthra and Correa, {Arlene M.} and Swisher, {Stephen G.} and Wayne Hofstetter and Chao, {K. S Clifford} and Hung, {Mien Chie} and Ajani, {Jaffer A.}",
year = "2007",
month = "6",
day = "1",
doi = "10.1158/1055-9965.EPI-06-1083",
language = "English (US)",
volume = "16",
pages = "1200--1205",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Clinical biology of esophageal adenocarcinoma after surgery is influenced by nuclear factor-κB expression

AU - Izzo, Julie G.

AU - Malhotra, Usha

AU - Wu, Tsung Teh

AU - Luthra, Rajalakshmi

AU - Correa, Arlene M.

AU - Swisher, Stephen G.

AU - Hofstetter, Wayne

AU - Chao, K. S Clifford

AU - Hung, Mien Chie

AU - Ajani, Jaffer A.

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Background: The expression of transcriptional factor nuclear factor κB (NF-κB) in untreated esophageal cancer specimens from patients who receive preoperative chemoradiation is associated with aggressive clinical biology. We hypothesized that nuclear NF-κB would define clinical biology even when surgery is used as primary therapy. Methods: Consecutive patients who did not receive any preoperative therapy were selected. Surgical cancer specimens were examined for nuclear NF-κB and correlated with overall survival (OS) and disease-free survival (DFS). Results: One hundred twenty-three patients (stage I, 9%; stage II, 24%; stage III, 53%; stage IV, 15%) with adenocarcinoma who underwent surgery as primary therapy were analyzed. Most patients were men (90%) and the median age was 63 years. For all 123 patients, the median DFS was 21 months and the median OS was 28 months. Nuclear NF-κB was associated with shortened DFS (P = 0.001) in 123 patients but also in stage II (P = 0.03) and stage III (P = 0.04). Nuclear NF-κB was associated with shortened OS (P = 0.002) in 123 patients and in stage II (P = 0.04) and showed trend in stage III (P = 0.17). Numbers are too small for stages I and IV. In multivariate models, nuclear NF-κB was an independent predictor for both DFS and OS (P = 0.005 and P = 0.01). Conclusions: Our data are the first to show that NF-κB status significantly correlates with DFS and OS for patients with esophageal adenocarcinoma undergoing surgery as primary therapy. NF-κB is an independent prognosticator of outcome, even for individual stages (e.g., stages II and III). More comprehensive molecular studies could help the design of strategies to individualize therapy of esophageal adenocarcinoma.

AB - Background: The expression of transcriptional factor nuclear factor κB (NF-κB) in untreated esophageal cancer specimens from patients who receive preoperative chemoradiation is associated with aggressive clinical biology. We hypothesized that nuclear NF-κB would define clinical biology even when surgery is used as primary therapy. Methods: Consecutive patients who did not receive any preoperative therapy were selected. Surgical cancer specimens were examined for nuclear NF-κB and correlated with overall survival (OS) and disease-free survival (DFS). Results: One hundred twenty-three patients (stage I, 9%; stage II, 24%; stage III, 53%; stage IV, 15%) with adenocarcinoma who underwent surgery as primary therapy were analyzed. Most patients were men (90%) and the median age was 63 years. For all 123 patients, the median DFS was 21 months and the median OS was 28 months. Nuclear NF-κB was associated with shortened DFS (P = 0.001) in 123 patients but also in stage II (P = 0.03) and stage III (P = 0.04). Nuclear NF-κB was associated with shortened OS (P = 0.002) in 123 patients and in stage II (P = 0.04) and showed trend in stage III (P = 0.17). Numbers are too small for stages I and IV. In multivariate models, nuclear NF-κB was an independent predictor for both DFS and OS (P = 0.005 and P = 0.01). Conclusions: Our data are the first to show that NF-κB status significantly correlates with DFS and OS for patients with esophageal adenocarcinoma undergoing surgery as primary therapy. NF-κB is an independent prognosticator of outcome, even for individual stages (e.g., stages II and III). More comprehensive molecular studies could help the design of strategies to individualize therapy of esophageal adenocarcinoma.

UR - http://www.scopus.com/inward/record.url?scp=34250832837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250832837&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-06-1083

DO - 10.1158/1055-9965.EPI-06-1083

M3 - Article

C2 - 17548685

AN - SCOPUS:34250832837

VL - 16

SP - 1200

EP - 1205

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 6

ER -